Drug Discovery World
JULY 20, 2023
Chemspace’s compound libraries are now accessible through Arrayjet’s SMM CRO/CMO services for assay development, contract screening and contract array manufacturing. SMMs enable high-throughput screening of compound libraries against targets of interest. PROTAC), and training AI drug discovery models.
Drug Discovery World
OCTOBER 4, 2022
William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . Overcoming sector challenges . Furthermore, the global need is about seven times greater than the US.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
FEBRUARY 22, 2024
Libra Therapeutics is a San Diego-based biotech focused on developing novel disease-modifying therapeutics, which restore the cellular balance that is disrupted in neurodegenerative diseases. Libra’s pipeline targets mechanisms that can mitigate protein pathology associated with CNS degenerative disorders.
Drug Discovery World
JANUARY 23, 2023
We witnessed the unprecedented pace of vaccine development, fuelled by cutting-edge mRNA technology. Our goal was to quickly identify existing therapeutics that could be repurposed for Covid-19 treatment by screening a library of approved and late-stage development drugs against a disease model in our platform.
Drug Discovery World
AUGUST 15, 2023
Although such electrophysiological systems may be more predictive of potential cardiac safety and efficacy than non-functional binding assays, many apparently attractive new drugs are still being discontinued later in development. Unexpected late-stage failures in drug development are, of course, the costliest.
Expert insights. Personalized for you.
40 
Let's personalize your content